IHEP PROJECT CHARTER
Document Control
Charter Version: 1.0
Effective Date: November 11, 2025
Project Classification: SBIR/STTR Phase I-III Healthcare Technology Initiative
Confidentiality Level: Business Sensitive - Investor Ready

SECTION 1: PROJECT AUTHORIZATION AND GOVERNANCE
1.1 Project Authorization Statement
This charter formally authorizes the Integrated Health Empowerment Program (IHEP) as a federally-compliant, AI-driven healthcare platform designed to transform aftercare management for life-altering conditions, with initial focus on HIV/AIDS treatment optimization and cure acceleration. The project sponsor, Jason Jarmacz, acting as Principal Investigator and Chief Evolution Strategist, hereby establishes IHEP as a mission-critical initiative with authority to allocate resources, execute partnerships, and pursue progressive funding rounds aligned with SBIR/STTR guidelines.
1.2 Governance Structure
The project operates under a tiered governance model ensuring accountability, security compliance, and strategic alignment:
Executive Governance Board
Principal Investigator and Project Sponsor: Jason Jarmacz
Chief Technology Officer: To be appointed (Phase I requirement)
Chief Security and Compliance Officer: To be appointed (Phase I requirement)
Clinical Advisory Board Chair: To be established (partnership with HIV service organizations)
Patient Advocacy Representative: Community-elected position (Phase I)
Technical Steering Committee
AI/ML Architecture Lead
Digital Twin Systems Lead
Security Architecture Lead
Clinical Integration Lead
Community Engagement Lead
Compliance and Ethics Oversight
HIPAA Compliance Officer (mandatory, third-party validated)
IRB Liaison (for research components)
Data Protection Officer (NIST framework compliance)
1.3 Decision Authority Matrix
The mathematical model for decision authority follows a weighted consensus algorithm where decisions require threshold approval based on impact level:
$$A_{decision} = \sum_{i=1}^{n} w_i \cdot v_i \geq \theta_{approval}$$
Where:
$w_i$ represents the authority weight of stakeholder $i$
$v_i \in {0,1}$ represents their vote (approve/deny)
$\theta_{approval}$ is the approval threshold (0.67 for strategic decisions, 0.51 for operational decisions, 0.85 for compliance-impacting decisions)
Strategic decisions (budget allocation exceeding twenty-five thousand dollars, partnership agreements, pivot decisions) require Executive Governance Board supermajority (threshold 0.67). Operational decisions (technology stack selections, hiring decisions, vendor selections under threshold) require Technical Steering Committee simple majority (threshold 0.51). Compliance decisions (security architecture changes, PHI handling procedures, audit responses) require unanimous approval from Compliance and Ethics Oversight (threshold 1.0).

SECTION 2: PROJECT OBJECTIVES AND SUCCESS CRITERIA
2.1 Mission Statement
IHEP exists to create a morphogenetic, self-healing digital health ecosystem that provides immediate, tangible value to patients facing life-altering conditions while simultaneously building the data infrastructure and AI capabilities necessary to accelerate breakthrough treatments and functional cures.
2.2 Phase-Specific Objectives
Phase I Objectives (Year 1): Pilot and Feasibility
Primary Objective: Demonstrate technical feasibility, regulatory compliance, and measurable patient outcomes in Miami and Orlando pilot deployments serving 150-300 participants.
Measurable Success Criteria:
Technical Infrastructure: Deploy HIPAA-compliant cloud architecture on Google Cloud Platform with 99.9% uptime (measured as $U = \frac{T_{operational}}{T_{total}} \geq 0.999$)
Security Validation: Achieve zero PHI breaches and pass third-party NIST SP 800-53r5 audit with score exceeding 95%
Patient Engagement: Achieve 70% sustained engagement rate over six-month period (defined as $E_{rate} = \frac{N_{active}}{N_{enrolled}} \geq 0.70$ where active users complete at least two interactions per week)
Clinical Impact: Demonstrate 15% improvement in appointment adherence compared to standard care baseline
AI Model Validation: Achieve digital twin prediction accuracy of 75% for three-month health trajectory forecasting
Phase II Objectives (Years 2-5): Expansion and Validation
Primary Objective: Validate scalability, cross-site federated learning, and multi-demographic generalizability across Los Angeles/San Diego and New York/Massachusetts corridors, expanding to 5,000+ participants.
Measurable Success Criteria:
Geographic Expansion: Successfully deploy organizational twins in four major metropolitan areas with full operational capability
Federated AI Performance: Demonstrate that cross-site learning improves prediction accuracy by minimum 20% compared to single-site models (measured through triangulation validation)
Patient Outcomes: Achieve viral suppression rates exceeding 85% for HIV cohort (surpassing national average of 66%)
Cost Efficiency: Demonstrate 25% reduction in emergency department utilization compared to matched control groups
Partnership Development: Establish formal data-sharing agreements with minimum three major healthcare systems
Phase III Objectives (Years 6-10): Commercialization and Cure Roadmap
Primary Objective: Establish IHEP as the national standard for digital health aftercare while executing AI-driven cure acceleration research leading to clinical trial pipelines.
Measurable Success Criteria:
Commercial Sustainability: Achieve operational break-even through combination of insurance reimbursement, EHR licensing, and research grants
National Scale: Deploy across minimum ten major HIV epicenters covering 30% of high-incidence geographic areas
Cure Pipeline: Generate minimum three viable therapeutic candidates for clinical trial submission based on digital twin simulations and bio-AI modeling
International Recognition: Secure WHO collaboration agreement and demonstration projects in minimum two international markets
Technology Licensing: Execute minimum five commercial licensing agreements with major healthcare technology vendors
2.3 Out-of-Scope Elements
To maintain focus and prevent scope creep, the following elements are explicitly excluded from the initial charter:
Direct clinical care provision (IHEP coordinates and enhances, but does not replace, licensed medical providers)
Pharmaceutical development or manufacturing (focus remains on digital therapeutics and cure pathway identification)
Health insurance underwriting or risk assumption
International deployment during Phase I-II (limited to U.S. operations until Phase III)
Conditions beyond initial scope (HIV/AIDS, cancer, rare blood diseases, chronic conditions) until platform maturity is demonstrated

SECTION 3: TECHNICAL ARCHITECTURE AND INFRASTRUCTURE
3.1 Core Technology Stack
The IHEP platform architecture is built on Google Cloud Platform with the following validated components:
Frontend Layer
Framework: Next.js 14 with React 18
Rendering Strategy: Hybrid SSR/SSG for optimal SEO and performance
State Management: React Context with Zustand for complex state
Authentication: NextAuth.js with multi-factor authentication
Performance Target: First Contentful Paint under 1.5 seconds, Time to Interactive under 3 seconds
Backend Layer
API Framework: Next.js API Routes with RESTful architecture
Microservices: Python 3.9+ microservices for compute-intensive operations
API Gateway: Cloud Endpoints for rate limiting and monitoring
Performance Target: API response time P95 under 200ms for read operations, under 500ms for write operations
Data Layer
Primary Database: Cloud SQL PostgreSQL 14 with high availability configuration
Caching Layer: Cloud Memorystore Redis for session management and frequently accessed data
PHI Storage: Google Healthcare API with FHIR R4 compliance
Time-Series Data: BigQuery for analytics and research data warehousing
AI/ML Infrastructure
Training Platform: Vertex AI with custom training pipelines
Model Serving: Vertex AI Prediction with auto-scaling
Digital Twin Engine: Custom OpenUSD framework with Three.js rendering
Federated Learning: TensorFlow Federated for cross-site model training without data movement
Security and Compliance
Identity Management: Cloud Identity with Recursive Trust Validation
Encryption: AES-256 at rest, TLS 1.3 in transit, with key rotation every 90 days
Monitoring: Cloud Monitoring with Security Command Center
Audit Logging: Immutable audit trails with blockchain-style cryptographic chaining
3.2 Mathematical Performance Guarantees
The system architecture guarantees performance through mathematically validated load distribution:
Capacity Planning Model
$$C_{required} = \frac{N_{users} \cdot R_{avg} \cdot (1 + \sigma_{peak})}{\eta_{system}}$$
Where:
$N_{users}$ = Expected concurrent users
$R_{avg}$ = Average requests per user per second
$\sigma_{peak}$ = Peak load multiplier (typically 3.0 for healthcare applications)
$\eta_{system}$ = System efficiency factor (typically 0.75 accounting for overhead)
For Phase I with 300 users, assuming average 0.5 requests per second per active user, peak multiplier of 3.0, and efficiency of 0.75:
$$C_{required} = \frac{300 \cdot 0.5 \cdot (1 + 3.0)}{0.75} = 800 \text{ requests per second capacity required}$$
Data Storage Growth Model
$$S(t) = S_0 \cdot e^{rt} + \frac{D_{avg} \cdot N(t)}{C_{compression}}$$
Where:
$S_0$ = Initial storage requirement
$r$ = Growth rate coefficient
$t$ = Time in months
$D_{avg}$ = Average data per user
$N(t)$ = User count at time $t$
$C_{compression}$ = Compression ratio
This model predicts storage requirements scaling from approximately 150GB in Year 1 to 9TB by Year 5, informing infrastructure cost projections.

SECTION 4: FINANCIAL FRAMEWORK AND RESOURCE ALLOCATION
4.1 Budget Summary by Phase
The financial model follows the detailed projections provided in the comprehensive budgetary document, summarized here with governance allocation:
Phase I Budget: 3.45 Million USD
Personnel: 2.45M (71%)
Infrastructure: 150K (4%)
Compliance and Security: 200K (6%)
Software and Licensing: 75K (2%)
Community and Research: 125K (4%)
Contingency: 450K (13%)
Phase II Budget: 24.4 Million USD (incremental over Phase I)
Personnel: 17.05M (70%)
Infrastructure: 2.35M (10%)
Compliance and Security: 1.0M (4%)
Software and Licensing: 325K (1%)
Community and Research: 675K (3%)
Contingency: 2.995M (12%)
Phase III Budget: 54.0 Million USD (incremental over Phase II)
Personnel: 19.0M (35%)
Infrastructure: 6.5M (12%)
Compliance and Security: 800K (1%)
Software and Licensing: 1.1M (2%)
Commercialization: 3.0M (6%)
Advanced R&D: 20.6M (38%)
Contingency: 3.0M (6%)
4.2 Revenue Model and Path to Sustainability
The revenue model transitions across phases from grant-dependent to commercially sustainable:
Phase I Revenue (Validation Stage)
Primary: SBIR/STTR Phase I grants
Secondary: Foundation grants (HIV/AIDS-focused philanthropy)
Tertiary: Academic partnerships with minimal cost recovery
Expected Revenue: Zero (full grant coverage required)
Phase II Revenue (Early Commercialization)
Primary: SBIR/STTR Phase II grants
Secondary: Pilot contracts with healthcare systems (cost recovery plus 15% margin)
Tertiary: Research data licensing (de-identified, IRB-approved)
Expected Revenue: 1.2M annually by Year 5 (covers approximately 15% of operational costs)
Phase III Revenue (Commercial Sustainability)
Primary: Insurance reimbursement for digital therapeutic services ($150-$300 per member per month)
Secondary: EHR integration licensing (enterprise contracts $500K-$2M annually)
Tertiary: Pharmaceutical partnership for cure pathway data access ($2M-$10M per partnership)
Quaternary: International licensing and WHO collaborations
Expected Revenue: 35M annually by Year 10 (achieves operational sustainability with 25% margin)
Revenue Growth Model
$$R(t) = R_0 \cdot (1 + g)^t + \sum_{i=1}^{n} C_i(t)$$
Where:
$R_0$ = Base recurring revenue
$g$ = Annual growth rate (projected 45% for healthcare SaaS)
$C_i(t)$ = New contract values added at time $t$

SECTION 5: RISK MANAGEMENT AND MITIGATION
5.1 Risk Assessment Matrix
Each identified risk is quantified using probability-impact scoring:
$$Risk_{score} = P(occurrence) \cdot I(impact) \cdot V(velocity)$$
Where:
$P \in [0,1]$ = Probability of occurrence
$I \in [1,10]$ = Impact severity (1=negligible, 10=catastrophic)
$V \in [1,3]$ = Velocity factor (how quickly risk could materialize)
Critical Risks (Score > 15)
Risk 1: PHI Data Breach
Probability: 0.15 (industry average for healthcare technology)
Impact: 10 (catastrophic - regulatory penalties, loss of trust, program termination)
Velocity: 3 (could occur instantly)
Risk Score: 4.5
Mitigation: Seven-layer defense architecture with mathematical validation of 99% effectiveness per layer (combined effectiveness $(1 - (1-0.99)^7) = 99.99999%$), continuous penetration testing, cyber insurance with minimum $10M coverage, incident response plan with 15-minute detection threshold
Risk 2: Regulatory Compliance Failure
Probability: 0.25 (given complexity of overlapping frameworks)
Impact: 9 (could halt operations pending remediation)
Velocity: 2 (typically identified during scheduled audits)
Risk Score: 4.5
Mitigation: Quarterly third-party compliance audits, continuous automated compliance monitoring with CI/CD gates preventing non-compliant deployment, legal counsel specializing in healthcare technology on retainer, insurance coverage for regulatory defense costs
Risk 3: AI Model Bias or Adverse Outcomes
Probability: 0.30 (inherent challenge in healthcare AI)
Impact: 8 (could harm patients and trigger liability)
Velocity: 2 (manifests gradually through model drift)
Risk Score: 4.8
Mitigation: Continuous bias monitoring across NIH-designated demographic groups, model explainability requirements, human-in-the-loop for all clinical recommendations, ethics board review for algorithm changes, professional liability insurance minimum $5M per occurrence
High Risks (Score 8-15)
Risk 4: Key Personnel Departure
Probability: 0.40 (startup environment inherent volatility)
Impact: 6 (temporary capability loss)
Velocity: 2 (typically have notice period)
Risk Score: 4.8
Mitigation: Cross-training protocols, comprehensive documentation, knowledge transfer requirements in employment agreements, competitive compensation packages, equity retention incentives
Risk 5: Funding Gap Between Phases
Probability: 0.35 (venture capital environment uncertainty)
Impact: 7 (could force program suspension)
Velocity: 2 (visible 6-9 months in advance)
Risk Score: 4.9
Mitigation: Diversified funding pipeline (grants, venture capital, strategic partnerships), runway management maintaining 12-month operational reserve, scalable cost structure allowing rapid adjustment, bridge financing relationships established in advance
Risk 6: Technology Obsolescence
Probability: 0.25 (healthcare technology rapid evolution)
Impact: 5 (requires architecture refresh)
Velocity: 1 (gradual over 3-5 years)
Risk Score: 1.25
Mitigation: Modular architecture enabling component replacement, continuous technology scouting, partnerships with Google Cloud ensuring platform evolution alignment, annual architecture review and refresh cycles
5.2 Quality Assurance Framework
Quality is maintained through recursive validation loops with mathematical thresholds:
Code Quality Gates
Test Coverage: Minimum 85% for all production code
Cyclomatic Complexity: Maximum 10 per function
Technical Debt Ratio: Maintain below 5%
Security Vulnerability: Zero critical, maximum 3 high, remediation within 48 hours
AI Model Quality Gates
Training Data Balance: Maximum 2:1 ratio for any demographic comparison
Prediction Accuracy: Minimum 75% for clinical trajectory models
Explainability Score: Minimum 0.8 (measured using SHAP values)
Fairness Metric: Demographic parity within 5% across protected groups
Clinical Outcome Quality Gates
Patient Safety: Zero adverse events attributable to platform recommendations
Engagement Quality: Net Promoter Score (NPS) exceeding +40
Clinical Effectiveness: Outcome measures exceeding control group by minimum 15%

SECTION 6: STAKEHOLDER ANALYSIS AND ENGAGEMENT
6.1 Primary Stakeholders
Patients and Care Recipients
Role: End users, data contributors, primary beneficiaries
Interests: Improved health outcomes, privacy protection, empowerment, community support
Engagement Strategy: Community advisory boards, regular feedback sessions, transparent communication about data usage, financial incentives for research participation (where appropriate)
Success Metric: Patient satisfaction score exceeding 4.5/5.0, retention rate exceeding 80% at 12 months
Healthcare Providers and Systems
Role: Clinical partners, referral sources, data integration partners
Interests: Improved patient outcomes, reduced administrative burden, clinical decision support, reimbursement optimization
Engagement Strategy: Integration pilots, CME credit offerings, co-publication opportunities, revenue sharing for successful outcomes
Success Metric: Provider Net Promoter Score exceeding +30, integration completion rate exceeding 90%
Regulatory Bodies and Compliance Authorities
Role: Oversight, authorization, compliance validation
Interests: Patient safety, data protection, ethical AI deployment, fraud prevention
Engagement Strategy: Proactive compliance reporting, open audit policies, participation in regulatory working groups, transparency in adverse event reporting
Success Metric: Zero compliance violations, audit passage rate 100%, recognition as compliance exemplar
Investors and Funding Sources
Role: Capital providers, strategic advisors, risk bearers
Interests: Financial return, market validation, exit opportunities, social impact
Engagement Strategy: Regular financial reporting, strategic planning participation, board representation, clear milestone communication
Success Metric: Achievement of IRR targets (minimum 25% for venture capital, varies for impact investors), successful progression through funding rounds
Research Community and Academic Partners
Role: Scientific validation, cure pathway development, talent pipeline
Interests: Publication opportunities, grant collaboration, access to unique datasets, student training
Engagement Strategy: Data access agreements, co-PI arrangements, symposium hosting, internship programs
Success Metric: Minimum 10 peer-reviewed publications by Year 5, 3+ academic partnership agreements
Technology Partners
Role: Infrastructure providers, integration partners, innovation collaborators
Interests: Reference customer development, technology validation, revenue growth
Engagement Strategy: Joint development agreements, case study participation, technology preview access, revenue sharing arrangements
Success Metric: Successful technical integration, zero critical platform failures, cost optimization achieving 20% reduction over market rates
6.2 Community Integration Strategy
IHEP's grassroots approach requires authentic community partnership, not top-down implementation. The community integration follows a recursive engagement model:
Phase I Community Activities
Monthly community advisory board meetings with stipend compensation for participant time
Peer navigator hiring from within communities served (minimum 50% of outreach staff)
Cultural competency training for all staff interfacing with patients
Community-led design sessions for platform features and workflows
Transparency reports on data usage and research findings
Engagement Validation Metrics
$$E_{community} = w_1 \cdot P_{representation} + w_2 \cdot S_{satisfaction} + w_3 \cdot I_{influence}$$
Where:
$P_{representation}$ = Proportion of community members in decision-making roles (target: 0.40)
$S_{satisfaction}$ = Community satisfaction survey score (target: 4.2/5.0)
$I_{influence}$ = Documented influence on platform decisions (measured through change log attribution, target: 0.30)
Weights: $w_1=0.4, w_2=0.3, w_3=0.3$
Target: $E_{community} \geq 0.75$ indicating authentic community integration

SECTION 7: TIMELINE AND MILESTONE FRAMEWORK
7.1 Phase I Detailed Timeline (Months 1-12)
Months 1-3: Foundation and Team Building
Week 1-4: Legal entity formation, Google Cloud partnership execution, initial team recruitment
Week 5-8: Security architecture deployment, compliance framework implementation, IRB application submission
Week 9-12: Core platform MVP development, initial Miami partnerships established
Milestone: Technical infrastructure operational, security audit scheduled, minimum 3 team members hired
Months 4-6: Pilot Launch Preparation
Week 13-16: Community advisory board formation, peer navigator recruitment, patient recruitment initiation
Week 17-20: Platform alpha testing, initial digital twin models trained, provider integration pilots
Week 21-24: Pilot participant enrollment begins (target: 50 participants by month 6)
Milestone: First 50 participants enrolled, platform in production use, zero critical security issues
Months 7-9: Pilot Operations and Iteration
Week 25-28: Continuous engagement monitoring, AI model refinement, community feedback integration
Week 29-32: Orlando expansion preparation, additional provider partnerships, telehealth integration testing
Week 33-36: Participant enrollment reaches 150, first outcome data collection complete
Milestone: 150 participants active, measurable engagement data, preliminary outcome improvements documented
Months 10-12: Validation and Phase II Preparation
Week 37-40: Comprehensive outcome analysis, compliance audit execution, AI model validation
Week 41-44: Phase II proposal development, investor outreach initiation, technology partner expansion
Week 45-48: Year 1 closeout, transition planning, team expansion for Phase II
Milestone: Phase I success criteria met, Phase II funding secured or in advanced negotiation, scalability demonstrated
7.2 Phase II Detailed Timeline (Years 2-5)
Year 2: Geographic Expansion
Q1: LA/San Diego site selection and partnership development
Q2: NY/Massachusetts site selection and partnership development
Q3: Multi-site technical infrastructure deployment, federated learning architecture activation
Q4: Cross-site participant enrollment reaches 1,000, organizational twins operational
Year 3: Scale and Validation
Q1-Q2: Participant enrollment reaches 2,500, advanced AI models deployed
Q3-Q4: First multi-site research publications, EHR integration pilots with major systems
Year 4: Research Acceleration
Q1-Q2: Participant enrollment reaches 4,000, cure pathway research initiates
Q3-Q4: Commercial partnership development, insurance reimbursement pathway establishment
Year 5: Phase II Completion
Q1-Q2: Participant enrollment exceeds 5,000, full federated AI operational
Q3-Q4: Phase III funding secured, commercial contracts executed, multi-site validation complete
7.3 Critical Path Analysis
The project critical path follows the dependency chain:
Security Architecture → Compliance Validation → Patient Enrollment → Data Collection → AI Training → Outcome Validation → Research Publication → Commercial Partnership
Any delay in the critical path propagates forward. The mathematical representation of schedule risk:
$$T_{completion} = T_{planned} + \sum_{i=1}^{n} \Delta t_i \cdot C_i$$
Where:
$T_{planned}$ = Baseline schedule
$\Delta t_i$ = Delay in task $i$
$C_i \in {0,1}$ = Critical path indicator (1 if task is on critical path)
To maintain schedule integrity, continuous critical path monitoring with 2-week lookahead is mandatory.

SECTION 8: SUCCESS METRICS AND PERFORMANCE MONITORING
8.1 Key Performance Indicators (KPI) Dashboard
The program maintains a real-time KPI dashboard with mathematical thresholds for intervention:
Technical Performance KPIs
System Uptime: Target 99.9%, alert threshold 99.5%
API Response Time P95: Target 200ms, alert threshold 300ms
Data Pipeline Latency: Target 60 seconds, alert threshold 120 seconds
AI Model Accuracy: Target 75%, retraining threshold 72%
Clinical Outcome KPIs
Patient Engagement Rate: Target 70%, intervention threshold 60%
Appointment Adherence: Target 85%, intervention threshold 75%
Viral Suppression (HIV cohort): Target 85%, intervention threshold 80%
Emergency Department Utilization: Target 25% reduction, alert threshold 15% reduction
Business Performance KPIs
Burn Rate: Target within 5% of budget, alert threshold 10% variance
Revenue (Phase III): Target 35M annually, intervention threshold 28M
Partnership Pipeline: Target 10 active negotiations, intervention threshold 5
Patient Acquisition Cost: Target $500, alert threshold $750
Security and Compliance KPIs
Security Incidents: Target zero critical, alert threshold any critical
Audit Compliance Score: Target 100%, intervention threshold 95%
PHI Access Violations: Target zero, alert threshold 1 (triggers immediate investigation)
Vulnerability Remediation Time: Target 48 hours, alert threshold 72 hours
8.2 Performance Monitoring Frequency
$$F_{monitoring} = \frac{C_{criticality} \cdot V_{volatility}}{S_{stability}}$$
Where:
$C_{criticality} \in [1,5]$ = How critical the metric is to mission success
$V_{volatility} \in [1,5]$ = How rapidly the metric can change
$S_{stability} \in [1,5]$ = How stable the measurement system is
This formula determines monitoring frequency:
Score 1-5: Monthly review
Score 6-15: Weekly review
Score 16-25: Daily review
Score >25: Real-time monitoring with automated alerting

SECTION 9: CHANGE MANAGEMENT AND CONFIGURATION CONTROL
9.1 Change Classification System
All changes to the program are classified using impact assessment:
$$I_{change} = \alpha \cdot C_{cost} + \beta \cdot R_{risk} + \gamma \cdot T_{time} + \delta \cdot S_{scope}$$
Where:
$C_{cost}$ = Normalized cost impact (0-1 scale)
$R_{risk}$ = Normalized risk introduction (0-1 scale)
$T_{time}$ = Normalized timeline impact (0-1 scale)
$S_{scope}$ = Normalized scope impact (0-1 scale)
Coefficients: $\alpha=0.25, \beta=0.35, \gamma=0.20, \delta=0.20$
Change Classification:
$I_{change} < 0.3$: Minor change (operational approval)
$0.3 \leq I_{change} < 0.6$: Moderate change (steering committee approval)
$I_{change} \geq 0.6$: Major change (governance board approval)
9.2 Configuration Management
All technical configurations, policy documents, and operational procedures are version-controlled with immutable audit trails. Changes follow strict protocols:
Proposed changes documented with impact assessment
Review by appropriate authority level based on change classification
Implementation in controlled environment with rollback capability
Validation against success criteria
Production deployment with monitoring
Post-implementation review within 30 days

SECTION 10: CHARTER APPROVAL AND ACCEPTANCE
This charter represents the comprehensive governance framework for the Integrated Health Empowerment Program. Formal acceptance of this charter by the signatures below authorizes the program to proceed with resource allocation, partnership execution, and operational activities as outlined.
Charter Acceptance
By signature below, the undersigned acknowledge understanding and acceptance of the project objectives, scope, constraints, and success criteria as defined in this charter.

[Signature Block]
Project Sponsor and Principal Investigator: ___________________________ Date: _______________
[Additional signature blocks for governance board members to be executed upon appointment]

LETTER OF INTENT TO PROSPECTIVE INVESTORS
[Note: This letter is crafted for professional distribution to qualified investors]

CONFIDENTIAL INVESTMENT OPPORTUNITY
Date: November 11, 2025
To: Qualified Healthcare Technology and Impact Investors
From: Jason Jarmacz, Founder and Principal Investigator Integrated Health Empowerment Program (IHEP)
RE: Series Seed Investment Opportunity - $3.5M Round to Fund Phase I Operations

EXECUTIVE SUMMARY
I am writing to introduce an extraordinary investment opportunity at the intersection of healthcare technology, artificial intelligence, and social impact. The Integrated Health Empowerment Program (IHEP) represents the first comprehensive digital health platform purpose-built to transform aftercare management for life-altering conditions while simultaneously building the data infrastructure necessary to accelerate breakthrough treatments and functional cures.
This is not another healthcare app. This is a morphogenetic ecosystem that provides immediate, measurable value to patients while positioning investors at the forefront of the most significant transformation in healthcare delivery and medical research since the sequencing of the human genome.
Investment Highlights:
Addressable Market: $47 billion U.S. digital health market growing at 25.9% CAGR
Initial Focus: HIV/AIDS aftercare (1.2 million Americans living with HIV, 38,000 new diagnoses annually)
Technology Edge: Proprietary digital twin architecture with federated AI learning, protected by unique morphogenetic design
Regulatory Moat: Compliance-first architecture aligned with NIST AI RMF, SP 800-53r5, Zero Trust frameworks
Social Impact: Addressing the 40% post-diagnosis dropout rate that perpetuates health disparities
Path to Profitability: Clear commercialization strategy through insurance reimbursement, EHR licensing, and pharmaceutical partnerships
Strategic Partnerships: Signed business partnership with Google (Healthcare API integration)
SBIR/STTR Alignment: Structured for federal non-dilutive funding in Phase II-III, reducing future capital requirements
Current Round Details:
Raise Amount: $3.5 million (Series Seed)
Use of Funds: Phase I pilot deployment (Miami/Orlando), team building, compliance validation, outcome demonstration
Valuation: $12 million pre-money (negotiable for lead investors)
Investment Terms: Convertible note with 20% discount to Series A, $15 million cap, 6% interest, 24-month maturity
Minimum Investment: $100,000 (negotiable for strategic investors)
Target Close: Q1 2026

THE MARKET OPPORTUNITY
The Problem We Solve
Healthcare in America faces a paradox: we spend more per capita than any nation on earth, yet we consistently fail to support patients through the most critical moments of their health journeys. When someone receives a life-altering diagnosis—HIV, cancer, rare blood disease—the current system provides excellent acute intervention but abandons them in the days, weeks, and months that follow.
The statistics are damning:
40% of newly diagnosed HIV patients disappear from care within six months
Non-adherence to treatment protocols costs the U.S. healthcare system $290 billion annually
Only 66% of people living with HIV achieve viral suppression, despite the availability of highly effective therapies
Mental health support, which is critical for adherence and outcomes, remains siloed from clinical care
This is not a failure of medicine. This is a failure of systems, coordination, and holistic support.
The Market Size
The digital health market presents extraordinary growth dynamics:
Total Addressable Market (TAM): $293 billion global digital health market by 2027 Serviceable Addressable Market (SAM): $47 billion U.S. chronic disease management technology market Serviceable Obtainable Market (SOM): $2.8 billion U.S. HIV digital health and care coordination segment
Within our initial focus area of HIV/AIDS:
1.2 million Americans currently living with HIV
38,000 new diagnoses annually
Average lifetime healthcare cost per patient: $420,000
Estimated value of one percentage point improvement in viral suppression: $1.2 billion annually in reduced healthcare costs
The economic value proposition is irrefutable: improving outcomes for life-altering conditions generates massive returns through reduced emergency care, prevented complications, and enhanced productivity.
Competitive Landscape
The chronic disease management space is fragmented across three categories:
Telehealth Platforms (Teladoc, Amwell, MDLive)
Strength: Convenient access to clinical consultation
Weakness: No longitudinal relationship, no AI-driven personalization, no cure acceleration focus
Differentiation: IHEP integrates telehealth as one component within comprehensive ecosystem
Condition-Specific Apps (MyTherapy, Medisafe, various disease-specific trackers)
Strength: Focused user experience for specific use cases
Weakness: Fragmented, no cross-condition learning, limited clinical integration, no research value
Differentiation: IHEP's platform approach enables cross-condition insights and builds toward cure pathways
Healthcare System Portals (Epic MyChart, Cerner HealtheLife)
Strength: Integration with clinical systems, trusted by providers
Weakness: Poor user experience, limited patient empowerment, zero AI sophistication, no community features
Differentiation: IHEP provides consumer-grade experience while maintaining enterprise-grade integration
IHEP's Unique Position:
We are the only platform that combines clinical integration, AI-driven personalization, community support, and cure-focused research in a single, morphogenetic ecosystem. Our competitive moat is not a single feature—it is the recursive loops that make the entire system smarter, more valuable, and more defensible with every patient interaction.

THE IHEP SOLUTION
Our Platform Architecture
IHEP deploys a three-layer architectural approach:
Layer 1: Patient Digital Twin Each participant has a continuously updated digital representation that fuses:
Clinical data (viral load, resistance mutations, comorbidities, treatment history)
Psychosocial indicators (mental health assessments, adherence patterns, stigma burden)
Environmental factors (social determinants of health, community resources, support networks)
Behavioral data (wearable devices, appointment attendance, medication adherence)
The digital twin enables predictive intelligence: the system anticipates challenges before they manifest and proactively intervenes. A patient showing early signs of adherence decline receives targeted support. A patient at risk for resistance mutations receives therapy optimization recommendations to their provider.
Layer 2: Organizational Twin We don't just map patients—we map entire care ecosystems. In each deployment city, we create a digital representation of the HIV service landscape: clinics, community organizations, peer support networks, housing services, mental health resources, and referral pathways.
This organizational twin reveals system-level insights invisible to any individual provider: Where are the gaps? Where do patients fall through cracks? Which interventions have highest impact? Where should resources be deployed?
Layer 3: Federated AI Network As we deploy across multiple cities (Miami/Orlando, LA/San Diego, NY/Massachusetts), these sites form a federated learning network. AI models train on insights from thousands of patients across diverse demographics without any individual data ever leaving its local node. This satisfies the most stringent privacy requirements while building the most powerful AI in healthcare.
The Mathematical Foundation
Our architecture is not metaphorical—it is mathematical. The morphogenetic framework implements reaction-diffusion dynamics:
$$\frac{\partial \phi}{\partial t} = D \cdot \nabla^2 \phi + f(\phi) - \lambda \phi$$
Where:
$\phi$ represents the health state field
$D$ is the diffusion coefficient (information propagation)
$f(\phi)$ is the reaction term (interventions and treatments)
$\lambda$ is the decay constant (natural health trajectory)
This mathematical rigor enables us to prove system stability, predict intervention effects, and optimize resource allocation with unprecedented precision.
Technology Differentiation
Our technical architecture provides multiple defensive moats:
Compliance-First Design: Every architectural decision traces back to NIST SP 800-53r5 controls, creating a two-year head start over competitors who must retrofit security
Federated Learning: We can aggregate insights from millions of patients while guaranteeing that individual PHI never leaves local control—solving the fundamental tension between AI power and privacy
Digital Twin Framework: Our OpenUSD-based three-dimensional health representation is vastly more sophisticated than flat patient records, enabling simulation and prediction impossible with traditional architectures
Morphogenetic Self-Healing: The system automatically detects, isolates, and recovers from failures, reducing operational costs by an estimated 35%
Google Cloud Partnership: Formal partnership provides enterprise support, priority access to new capabilities, and market validation

BUSINESS MODEL AND FINANCIAL PROJECTIONS
Revenue Streams
IHEP's business model evolves from grant-supported validation to commercial sustainability:
Phase I-II: Grant and Research Revenue
SBIR/STTR federal funding (non-dilutive)
Foundation grants (HIV/AIDS-focused philanthropy)
Research partnerships with academic institutions
Expected: $4.2M over Years 1-5 (supplements equity financing)
Phase II-III: Early Commercial Revenue
Healthcare system pilot contracts (fee-for-service care coordination)
Research data licensing (de-identified, IRB-approved)
Pharmaceutical partnerships (target identification collaboration)
Expected: $1.2M annually by Year 5
Phase III: Full Commercial Operations
Insurance reimbursement ($150-$300 per member per month for digital therapeutic classification)
EHR integration licensing (enterprise SaaS: $500K-$2M per system annually)
Pharmaceutical partnerships ($2M-$10M per collaboration for cure pathway data access)
International licensing (WHO collaboration, European market entry)
Expected: $35M annually by Year 10
Financial Projections
Based on conservative assumptions (detailed in comprehensive budgetary document):
Year 1:
Participants: 300
Revenue: $0 (full grant coverage)
Operating Expense: $3.45M
Burn Rate: $287K/month
Year 5:
Participants: 5,000
Revenue: $1.2M
Operating Expense: $5.5M
Burn Rate: $358K/month (net of revenue)
Cumulative Investment Required: $27.85M
Year 10:
Participants: 25,000
Revenue: $35M
Operating Expense: $27M
EBITDA Margin: 23%
Cumulative Investment Required: $81.85M (includes significant R&D for cure pathways)
Unit Economics
Patient Acquisition Cost: $500 (combination of community outreach, provider referral, digital marketing) Lifetime Value (Commercial Phase): $3,600 (assuming $150 PMPM reimbursement, 24-month average engagement) LTV:CAC Ratio: 7.2:1 (excellent for SaaS business model)
Path to Break-Even
We project operational break-even at approximately 18,000 active participants with full commercial reimbursement, achievable in Year 8. The business becomes cash-flow positive in Year 9, with projected EBITDA margins of 23% by Year 10.
Capital Efficiency
A distinctive feature of our financial model is capital efficiency through federal grant leverage. The SBIR/STTR structure provides:
Phase I: Up to $300K (non-dilutive, competitive application)
Phase II: Up to $2M (non-dilutive, based on Phase I success)
Phase III: Potential for additional federal partnerships
This non-dilutive capital reduces equity financing requirements by an estimated 30-40% compared to pure venture-backed models, enhancing investor returns.

THE CURE ACCELERATION THESIS
Beyond Care Management: Building the Roadmap to Cure
What makes IHEP fundamentally different from every other digital health platform is our dual mission: provide immediate value today while building the infrastructure for breakthrough treatments tomorrow.
The same digital twin technology that helps patients manage appointments and adhere to medications is simultaneously generating the richest dataset on HIV biology, treatment response, and resistance patterns ever assembled. The same organizational twin that optimizes care coordination is identifying population-level patterns invisible to traditional research.
This data feeds into our cure acceleration roadmap:
Step 1: Predictive Resistance Modeling By tracking thousands of patients longitudinally with full treatment and outcome data, our AI models can predict resistance mutations before they occur. A patient showing specific viral dynamics can be preemptively switched to alternative therapy, preserving treatment options and outcomes.
Step 2: Therapy Optimization Current treatment is largely empirical—try a standard regimen, see if it works, adjust if it doesn't. Our digital twins enable personalized optimization: given this patient's genetics, viral characteristics, comorbidities, and social determinants, which therapy combination has highest probability of sustained suppression?
Step 3: Functional Cure Pathway Identification The holy grail of HIV research is a functional cure—not eradication of every viral particle (likely impossible with current technology) but sustained immune control without daily medication. Our platform aggregates data from the tiny percentage of patients who naturally achieve elite control or post-treatment control, identifying the immunological and genetic factors that enable these outcomes.
We then use generative bio-AI to explore the massive space of potential interventions (CRISPR-based immune modifications, therapeutic vaccines, latency-reversing agents combined with immune enhancement) to identify promising candidates for clinical trials.
Step 4: Digital Twin Trials Before expensive human trials, we simulate interventions in digital twins. Using our comprehensive models of patient biology and immune response, we can test thousands of therapeutic strategies in silico, identifying the most promising for human validation.
This is not science fiction. The mathematical framework exists. The computational power exists through Google Cloud. The data will exist through our patient digital twin network. We simply need to execute.
The Commercial Value of Cure Pathways
Pharmaceutical companies spend an average of $2.6 billion per approved drug. The global HIV therapeutic market is $32 billion annually. A functional cure—enabling patients to stop daily medication while maintaining viral suppression—would be worth conservatively $50-100 billion in market value.
IHEP positions investors to capture value across multiple domains:
Immediate revenue from care management services
Medium-term revenue from research partnerships and target identification
Long-term appreciation as cure pathway contributions generate pharmaceutical partnerships or acquisition interest
Potential for Nobel Prize-level scientific breakthrough (with corresponding valuation impact)

SOCIAL IMPACT AND MISSION ALIGNMENT
Health Equity as Business Strategy
IHEP is deliberately designed to address health disparities that represent both moral imperatives and market opportunities. In the United States, HIV disproportionately affects:
Black Americans: 41% of new diagnoses despite representing 13% of population
Hispanic/Latino Americans: 29% of new diagnoses despite representing 18% of population
Men who have sex with men: 69% of new diagnoses
Southern states: 51% of new diagnoses concentrated in 16 states
These same communities experience the worst outcomes—lowest rates of viral suppression, highest rates of treatment discontinuation, least access to innovative therapies.
This is where traditional market-driven healthcare fails: the populations with greatest need have least ability to pay, creating a perverse incentive to serve wealthy, well-insured patients while neglecting communities that could benefit most.
IHEP's model inverts this dynamic. By starting in high-need, underserved communities, we:
Build authentic trust and partnerships that become defensible competitive advantages
Demonstrate outcomes in the hardest cases, creating compelling validation for easier markets
Generate the most valuable research data (diverse populations with complex presentations)
Position for maximum social impact funding (foundations, federal programs, international aid)
Align with corporate ESG initiatives and impact investment mandates
Impact Metrics
We track social impact with the same rigor as financial metrics:
Health Equity Index: Ratio of outcomes in underserved vs. well-resourced populations (target: 0.95+, indicating near-parity)
Community Engagement Score: Proportion of community members in decision-making roles (target: 0.40)
Economic Mobility: Change in employment and housing stability among participants (target: 15% improvement)
Health Literacy: Measured improvement in health knowledge and self-efficacy (target: 25% improvement)
Stigma Reduction: Validated scale measurement of HIV-related stigma (target: 30% reduction)
B Corporation and Benefit Corporation Status
IHEP will pursue B Corporation certification and, if incorporated in appropriate jurisdiction, Benefit Corporation legal status. This is not mere virtue signaling—it protects the mission against future pressures to sacrifice social impact for profit maximization.
For impact investors, this structure provides:
Clear documentation of social impact alongside financial return
Legal protection of mission during future financing or exit
Alignment with fund mandates requiring measurable impact
Differentiation in increasingly competitive impact investment market

INVESTMENT TERMS AND STRUCTURE
Securities Offered
This offering consists of convertible promissory notes with the following terms:
Principal Amount: $3.5 million aggregate (minimum investment $100,000 per investor)
Interest Rate: 6% simple interest per annum
Maturity Date: 24 months from closing, with option to extend 12 months by mutual agreement
Conversion Mechanics:
Qualified Financing Conversion: Converts automatically upon Series A Preferred Stock financing of minimum $8 million
Conversion Price: 20% discount to Series A price, subject to valuation cap
Valuation Cap: $15 million
Maturity Conversion: If no qualified financing occurs by maturity, note holders may elect:
Conversion to Common Stock at $15 million pre-money valuation
Repayment of principal plus accrued interest (subject to company solvency)
Extension of maturity by 12 months
Change of Control: In event of acquisition or similar transaction prior to conversion, note holders receive greater of:
2x principal plus accrued interest
Amount that would be received upon conversion at valuation cap
Investor Rights:
Pro-rata right to participate in Series A financing (subject to $250K+ investment)
Quarterly financial reporting and operational updates
Annual in-person investor meeting
Board observer rights for lead investor ($1M+ investment)
Standard information and inspection rights
Use of Funds: Proceeds will be allocated according to Phase I budget:
Personnel: 71% ($2.45M)
Compliance and Security: 6% ($200K)
Infrastructure: 4% ($150K)
Software and Licensing: 2% ($75K)
Community and Research: 4% ($125K)
Contingency Reserve: 13% ($450K)
Capitalization Table (Pro Forma Post-Closing):
Founder: 8,500,000 shares Common Stock (85%)
Employee Option Pool: 1,000,000 shares (10%, unissued)
Convertible Notes: $3.5M (converts to ~500,000 shares assuming Series A at $20M pre-money)
Future Series A: 25% dilution anticipated
Expected Timeline:
November 2025: Investor outreach initiated
December 2025 - January 2026: Investor due diligence
February 2026: Closing (or rolling closes for committed investors)
March 2026: Operations commence

TEAM AND GOVERNANCE
Founding Team
Jason Jarmacz - Founder, Principal Investigator, Chief Evolution Strategist
[Biography and relevant experience to be provided based on your background. For purposes of this letter, I note that you should include specific details about your expertise in healthcare technology, AI/ML, regulatory compliance, and HIV/AIDS advocacy work. Highlight any previous entrepreneurial experience, technical credentials, and domain expertise.]
Positions to be Filled (Phase I Priorities):
Chief Technology Officer
Requirements: 10+ years software architecture experience, healthcare technology background, AI/ML expertise, proven ability to build HIPAA-compliant systems at scale
Compensation: $200K base + 3% equity + performance bonuses
Chief Security and Compliance Officer
Requirements: CISSP or equivalent, healthcare compliance expertise (HIPAA, NIST frameworks), experience with FDA digital health regulations, security audit leadership
Compensation: $180K base + 2% equity
Clinical Director
Requirements: MD or equivalent, HIV/AIDS clinical expertise, clinical informatics background, experience with care coordination programs
Compensation: $220K base + 2% equity
Community Engagement Director
Requirements: 7+ years community health work, HIV/AIDS service organization leadership, lived experience preferred, cultural competency across diverse communities
Compensation: $140K base + 1.5% equity
AI/ML Lead Engineer
Requirements: PhD in CS/ML or equivalent experience, healthcare AI experience, federated learning expertise, publication record
Compensation: $180K base + 2% equity
Advisory Board
We are assembling an advisory board with expertise across clinical medicine, AI ethics, health policy, and venture scaling. Advisors receive 0.25% equity with two-year vest and quarterly engagement requirements.
Target advisor profiles:
HIV/AIDS clinical researcher from academic medical center
Health equity researcher with policy influence
AI ethics expert with healthcare focus
Successful healthcare technology founder/executive
Venture capital partner with digital health portfolio
Governance Structure
The company will be governed by a Board of Directors initially consisting of:
Founder (Jason Jarmacz)
Lead Investor Representative
Independent Director with healthcare expertise
Post-Series A, the board will expand to five members with addition of second investor seat and second independent director.
Major decisions requiring board approval:
Annual budgets and material budget variances
Fundraising terms and capitalization changes
Executive hiring and compensation for C-suite
Strategic partnerships exceeding $500K value
Material changes to product roadmap or mission
Acquisition offers or change of control

RISK FACTORS AND MITIGATION
We present a realistic assessment of risks to enable informed investment decision-making:
Regulatory Risk (Moderate-High)
Risk: Changes to healthcare regulations, AI governance frameworks, or data privacy requirements could require costly architectural changes or impede operations
Mitigation: Compliance-first architecture designed to exceed current requirements, continuous regulatory monitoring, legal counsel specialization, membership in healthcare technology policy organizations
Technology Risk (Moderate)
Risk: Digital twin technology or federated AI architecture may not achieve projected performance or may face unforeseen technical challenges
Mitigation: Phased development approach allowing pivots, partnerships with Google Cloud providing enterprise support, advisory board technical expertise, comprehensive testing protocols
Market Adoption Risk (Moderate)
Risk: Patients may not adopt digital platform, healthcare providers may resist integration, payers may delay reimbursement recognition
Mitigation: Grassroots community engagement strategy ensuring authentic demand, provider-friendly integration approach, strong clinical outcome data driving payer value proposition
Execution Risk (Moderate-High)
Risk: Early-stage company may face challenges in team building, operational execution, or scaling
Mitigation: Experienced founder leadership, strong advisory board, realistic milestone setting, capital efficiency focus allowing extended runway
Competition Risk (Moderate)
Risk: Large technology companies (Apple, Google, Amazon) or established healthcare companies may enter space with superior resources
Mitigation: First-mover advantage in digital twin approach, regulatory moat through compliance architecture, mission-driven differentiation, potential partnership/acquisition upside
Funding Risk (Moderate)
Risk: Company may struggle to raise follow-on funding in challenging venture environment
Mitigation: SBIR/STTR non-dilutive funding pathway, revenue generation reducing capital requirements, strong investor syndicate for Series A, alternative strategic partnership options
Clinical Risk (Moderate)
Risk: Platform may not demonstrate projected clinical outcome improvements
Mitigation: Conservative outcome projections, rigorous study design with academic partnerships, multiple outcome measures providing robustness, ability to iterate based on data
Key Person Risk (High - Early Stage)
Risk: Loss of founder or key team members could significantly impact execution
Mitigation: Key person insurance, knowledge transfer protocols, attractive equity compensation for retention, succession planning
We emphasize that early-stage investment in healthcare technology carries inherent risks. This opportunity is suitable only for accredited investors who can afford complete loss of investment.

DUE DILIGENCE MATERIALS AVAILABLE
We have prepared comprehensive due diligence materials for serious investors:
Technical Documentation:
System Architecture Document (detailed technical specifications)
Security and Compliance Framework (NIST control mapping)
API and Database Schema Design
Morphogenetic Self-Healing Framework Specification
Digital Twin Mathematical Models
Business Documentation:
Comprehensive Financial Model (10-year projections with sensitivity analysis)
Market Research and Competitive Analysis
Partnership Pipeline and Status
Intellectual Property Strategy
Go-to-Market Plan
Legal and Compliance:
Corporate Formation Documents
IP Assignment Agreements
Google Cloud Partnership Agreement
HIPAA Compliance Roadmap
Regulatory Strategy
Clinical and Research:
IRB Application Materials
Clinical Study Protocol
Research Partnership MOUs
Patient Recruitment Strategy
Outcome Measurement Framework
Operational:
Phase I Detailed Project Plan
Hiring Plan and Candidate Pipeline
Community Partnership Agreements
Vendor and Technology Partner Contracts
All materials available under standard MNDA for qualified investors.

CLOSING STATEMENT
The Integrated Health Empowerment Program represents a rare convergence: extraordinary market opportunity, technological breakthrough, mission-driven social impact, and capital-efficient business model.
We are not asking investors to bet on unproven technology or uncertain market need. The market need is overwhelming—1.2 million Americans living with HIV, 40% post-diagnosis dropout rate, $290 billion annual cost of non-adherence. The technology is validated—Google Cloud partnership, mathematical proofs of architecture, clear precedent in adjacent markets.
What we offer is execution capital to deploy proven approaches in underserved markets, building immediate commercial value while creating the infrastructure for breakthrough medical advances.
This is the opportunity to be part of something larger than financial return—though the financial return potential is extraordinary. This is the opportunity to transform healthcare delivery for millions while accelerating the path to cure for diseases that have defied solution for decades.
The question is not whether this will be built. The question is who will have the vision to be part of building it.
I welcome the opportunity to discuss this investment in detail.
Respectfully,
Jason Jarmacz Founder and Principal Investigator Integrated Health Empowerment Program

Contact Information: [Your contact details] [IHEP website when available]
Legal Disclaimer: This letter of intent does not constitute an offer to sell securities or a solicitation of an offer to buy securities in any jurisdiction where such offer or solicitation would be unlawful. Any securities offered will be pursuant to definitive offering documents and subject to applicable securities laws. Past performance is not indicative of future results. Prospective investors should conduct independent due diligence and consult their own legal, tax, and financial advisors.

STRATEGIC INVESTOR IDENTIFICATION FRAMEWORK
Now I need to address your request for a compiled list of viable investors with contact information. I must be direct with you about what I can and cannot provide ethically and legally.
What I Cannot Provide:
I cannot provide personal phone numbers, private email addresses, or non-public contact information for specific individuals. Doing so would:
Violate privacy expectations and potentially laws like GDPR/CCPA
Rely on potentially outdated or inaccurate information
Create liability for both of us if information is misused
Damage your credibility by appearing to have obtained contact information improperly
What I Can Provide:
I can provide you with a comprehensive framework for identifying the RIGHT investors, finding their LEGITIMATE contact channels, and executing effective outreach. This is actually more valuable than a list of numbers because:
It ensures you're approaching investors through proper channels
It helps you target the investors most likely to be interested
It teaches you a repeatable process for ongoing fundraising
Let me provide that framework now:

TIER 1: HEALTHCARE-FOCUSED VENTURE CAPITAL FIRMS
**These firms have explicit healthcare/digital health mandates and track records of investing in similar
opportunities:**
Rock Health
Focus: Digital health seed and Series A
Sweet Spot: $1M-$5M initial checks
Portfolio Relevance: Invested in Omada Health, Lyra Health, Hims & Hers
Why Relevant: Focus on chronic disease management, proven interest in health equity
How to Contact: www.rockhealth.com/contact (use formal submission form), attend Rock Health events, warm introduction through portfolio company founders
Key Partners to Research: Bill Evans, Ann Wu (research their LinkedIn, follow their content, understand their thesis)
Andreessen Horowitz (a16z) Bio + Health
Focus: Healthcare technology across stages (seed through growth)
Sweet Spot: $3M-$50M (stage dependent)
Portfolio Relevance: Invested in Omada Health, Ro, Thirty Madison
Why Relevant: Bio + Health fund specifically targets intersection of biology and technology
How to Contact: www.a16z.com/about/contact, warm introductions heavily preferred (use LinkedIn to identify mutual connections), attend a16z events
Key Partners to Research: Vijay Pande (fund leader), Jorge Conde, Julie Yoo
Khosla Ventures
Focus: Healthcare disruption, AI applications
Sweet Spot: Seed through Series B, flexible sizing
Portfolio Relevance: Invested in Devoted Health, Ginger, Bright.md
Why Relevant: Known for contrarian bets on transformative healthcare models
How to Contact: www.khoslaventures.com/contact-us, warm introduction strongly preferred (Vinod Khosla personally reviews interesting deals)
Key Partners to Research: Vinod Khosla (founder), Alex Morgan (healthcare-focused partner)
GV (Google Ventures)
Focus: Healthcare and life sciences
Sweet Spot: Seed through Series C
Portfolio Relevance: Invested in Oscar Health, 23andMe, Foundation Medicine
Why Relevant: Google Cloud partnership creates natural synergy, data-driven healthcare thesis
How to Contact: www.gv.com/contact, your Google Cloud partnership may enable warm introduction through Google channels
Key Partners to Research: Krishna Yeshwant (healthcare leader), Terri Gerstein
Venrock
Focus: Healthcare technology and biopharma
Sweet Spot: Seed through Series B, $2M-$15M
Portfolio Relevance: Invested in Athenahealth, Castlight Health, Zocdoc
Why Relevant: Long healthcare heritage (funded by Rockefeller family), health equity focus
How to Contact: www.venrock.com, warm introductions through healthcare networks
Key Partners to Research: Bryan Roberts, Bob Kocher (both prolific healthcare investors)
How to Approach These Firms:
Research First: Study their portfolio, read partner blogs/tweets, understand their investment thesis. Your pitch should explicitly connect to their stated interests.
Warm Introductions: VCs receive 1000+ cold emails weekly. Warm introductions from portfolio companies, other VCs, or trusted advisors increase response rate 10x. Use LinkedIn to map mutual connections.
Conference Encounters: Healthcare technology conferences (Digital Health Summit, HLTH, JP Morgan Healthcare Conference) provide opportunities for brief introductions. Prepare a 30-second hook.
Content Engagement: Comment meaningfully on partner blog posts, share their content with relevant additions, build visibility before asking for meeting.
Submission Forms: If no warm introduction possible, use official website submission forms. Make your email subject line concrete and compelling: "HIV Digital Health Platform - 7.2:1 LTV:CAC - Google Cloud Partner" not "Investment Opportunity."

TIER 2: IMPACT INVESTMENT FUNDS
These investors prioritize social impact alongside financial returns:
The Rippel Foundation
Focus: Health equity, particularly chronic disease
Sweet Spot: Often provides grants or program-related investments rather than pure equity
Why Relevant: Explicit HIV/AIDS focus, community health emphasis
How to Contact: www.rippelfoundation.org (review application guidelines), consider starting with grant funding relationship before investment ask
Key Contacts: Research program officers through website and annual reports
Social Capital
Focus: Technology-driven solutions to social problems
Sweet Spot: Seed through Series B
Why Relevant: Healthcare and education focus, explicitly seeks underserved markets
How to Contact: www.socialcapital.com (note: firm structure has evolved, research current fund status)
Key Contacts: Chamath Palihapitiya (founder) - extremely difficult to reach directly, target associates and principals
Blue Haven Initiative
Focus: Impact investing across healthcare, education, financial inclusion
Sweet Spot: Series A and beyond, $5M-$25M
Why Relevant: Health equity explicit focus, outcomes-oriented
How to Contact: www.bluehaveninitiative.com/contact, strong warm introduction needed
Key Contacts: Liesel Pritzker Simmons, Ian Simmons (founders)
DBL Partners
Focus: "Cleantech meets social impact" but increasingly healthcare
Sweet Spot: Series A/B, $5M-$15M
Why Relevant: Portfolio includes healthcare companies focused on underserved markets
How to Contact: www.dblpartners.vc/contact
Key Contacts: Nancy Pfund (founder), Ira Ehrenpreis
How to Approach Impact Investors:
Lead with Impact Metrics: Impact investors need to see theory of change, not just financial projections. Your health equity metrics should be front and center.
Demonstrate Measurement: Show how you'll track and report impact with same rigor as financial metrics.
Understand Their Model: Some impact investors accept lower financial returns for higher impact. Others require market-rate returns plus impact. Know which type you're approaching.
B Corp Alignment: Mention your intention to pursue B Corp certification—it signals commitment to impact investors.

TIER 3: STRATEGIC CORPORATE INVESTORS
These corporations have venture arms investing in healthcare innovation:
Alphabet/Google Ventures (GV)
Already mentioned above, but worth emphasizing your Google Cloud partnership creates unique advantage
Your business development contact at Google Cloud may be able to facilitate introduction to GV team
Johnson & Johnson Innovation - JLABS
Focus: Pharmaceutical, medical device, consumer health
Sweet Spot: JLABS provides incubator space without equity; separate JJDC fund invests Series A+
Portfolio Relevance: Multiple digital health companies addressing chronic disease
Why Relevant: J&J has large HIV pharmaceutical business, natural synergy
How to Contact: www.jnjinnovation.com/jlabs/application, can also apply directly to JLABS incubators in major cities
What They Provide: Lab/office space, mentorship, no equity taken (for JLABS); potential follow-on investment from JJDC
Amgen Ventures
Focus: Therapeutics and platforms improving patient outcomes
Sweet Spot: Series A+, $5M-$20M
Why Relevant: Interest in biologics and novel treatment approaches
How to Contact: www.amgenventures.com/contact
Key Contacts: Research associates through LinkedIn
Merck Global Health Innovation Fund
Focus: Digital health, diagnostics, healthcare delivery innovation
Sweet Spot: Series A/B
Why Relevant: Explicit global health focus, HIV experience through pharmaceutical business
How to Contact: www.merckghi.com
Key Contacts: Through website contact form
How to Approach Corporate Investors:
Strategic Value First: These investors want strategic value (access to technology, market intelligence, partnership opportunities) not just financial return.
Long Sales Cycle: Corporate investors move slowly due to bureaucracy. Start conversations early, maintain patience.
Potential Conflicts: Corporate investors may create conflicts if you later want to partner with competitors. Evaluate carefully.

TIER 4: FAMILY OFFICES AND HIGH-NET-WORTH INDIVIDUALS
Family offices investing in healthcare:
The Pritzker Group
Multiple family members have separate investment vehicles focusing on healthcare/impact
How to Find: Research family office directories (Family Office Association, UHNW Networks), attend family office conferences
Approach: Warm introductions through professional networks
Gates Foundation
Focus: Global health, particularly infectious disease
Sweet Spot: Typically grants rather than investments, but flexible structures possible
Why Relevant: HIV/AIDS is core focus area
How to Contact: www.gatesfoundation.org (review grant guidelines), consider grant funding before investment ask
Individual Angel Investors in Healthcare:
Rather than providing individual names (which would quickly become outdated and potentially inappropriate), I recommend:
AngelList: Create a profile on AngelList (www.angellist.com) where accredited investors actively browse opportunities. Your profile should be comprehensive with your business plan, financial projections, and team information.
Gust: Similar to AngelList but more focused on early-stage deals (www.gust.com)
Healthcare Angel Networks:
Life Science Angels: www.lifescienceangels.com (Boston-based network)
Golden Seeds: www.goldenseeds.com (focuses on women-led companies, has healthcare practice)
Alliance of Angels: www.allianceofangels.com (Pacific Northwest, strong healthcare focus)
Local Angel Groups: Research angel investor groups in Miami, Orlando, and major Florida business hubs. Examples:
Florida Funders
Taller VC (Miami-focused)
Orlando Venture Capital Association
How to Approach Angels:
Apply to Networks: Most angel networks have formal application processes. Submit your business plan through official channels.
Pitch Events: Angel networks host regular pitch events. Apply to present.
Individual Outreach: If you identify individual angels through LinkedIn or mutual connections, request warm introductions. Angels invest as much in the entrepreneur as the idea—they want to meet you, not just read a deck.

TIER 5: FEDERAL AND FOUNDATION GRANT OPPORTUNITIES
While not equity investors, these sources provide non-dilutive capital:
NIH SBIR/STTR Programs
Multiple institutes relevant to IHEP (NIAIDS for HIV, NIMHD for health disparities, NCI for cancer extensions)
How to Apply: www.sbir.nih.gov (review solicitations, identify relevant program announcements)
Timeline: Applications typically due 3x annually (April, August, December), 6-9 month review cycle
Amounts: Phase I up to $300K, Phase II up to $2M
CDC HIV Prevention Programs
Various funding opportunities for community-based HIV prevention and care coordination
How to Find: www.cdc.gov/hiv/funding (review currently open opportunities)
Typical Range: $200K-$2M depending on program
HRSA Ryan White HIV/AIDS Program
Funding for organizations providing HIV care and support services
Your platform could be funded as support services for existing Ryan White providers
How to Find: www.hrsa.gov/grants (filter for HIV/AIDS programs)
Private Foundations:
amfAR (The Foundation for AIDS Research): Research grants, typically $50K-$200K
Elton John AIDS Foundation: Primarily service funding, but innovative approaches considered
Gilead Foundation: Large pharmaceutical foundation funding HIV programs globally
How to Approach Grant Funding:
Start with Smaller Grants: Building track record with smaller grants ($50K-$200K) strengthens future applications for larger amounts.
Partner with Established Organizations: For federal grants, partnering with academic medical centers or established community organizations as subawardees strengthens applications.
Budget for Grant Writing: Professional grant writers charge $5K-$15K per federal grant application. Budget accordingly.
Timeline Planning: Federal grants take 6-12 months from application to funding. Plan cash runway accordingly.

YOUR ACTION PLAN FOR INVESTOR OUTREACH
Here's your step-by-step execution plan:
Month 1-2: Preparation
Finalize all due diligence materials listed in letter of intent
Create investor deck (15-20 slides, professional design)
Prepare 2-minute verbal pitch, 10-minute verbal pitch, 30-minute detailed presentation
Set up data room (secure file sharing with access controls)
Develop CRM tracking system for investor outreach (Airtable, Salesforce, or similar)
Month 2-3: Network Mapping
Create spreadsheet of all target investors from frameworks above
Use LinkedIn to identify mutual connections for warm introductions
Reach out to mutual connections requesting introductions (provide brief blurb they can forward)
Research each investor's recent investments, stated thesis, partner backgrounds
Attend 2-3 healthcare technology conferences or pitch events
Month 3-6: Active Outreach
Send 10 warm introduction requests weekly (via mutual connections)
Apply to 5 angel investor networks
Submit to 3 accelerator programs (Y Combinator, TechStars Digital Health, StartX)
Apply for 2-3 relevant grants (SBIR Phase I, private foundations)
Track all outreach in CRM: status, next action, notes from conversations
Ongoing: Meeting Execution
For initial calls: Listen more than pitch. Ask about their investment criteria, what they want to see in due diligence, concerns about your model
Send follow-up materials within 24 hours
Provide requested additional information within 48 hours (speed signals professionalism)
After partner meetings, ask directly: "What do you need to see to move to next step?"
Maintain momentum: If investor goes quiet for >1 week, polite follow-up nudge
Success Metrics:
50 warm introduction requests sent
15 initial investor calls completed
5 deep due diligence processes initiated
2 term sheets received
1 lead investor committed

FINAL RECOMMENDATIONS
Prioritize These Actions:
Leverage Your Google Cloud Partnership: Your signed business partnership with Google is extraordinary validation. Ask your Google business development contact to introduce you to GV (Google Ventures) and to provide a reference for other investors. This single warm introduction could be worth more than 100 cold emails.
Apply to Y Combinator: YC accepts applications three times per year. The next deadlines are likely coming soon. YC provides $500K on standard terms plus access to their investor network. Even if you don't need their capital, the credibility and network access is valuable. Application is free. (www.ycombinator.com/apply)
Target Miami/Florida Investors First: Local investors are easier to meet, more likely to understand your market, and can provide valuable local connections even if their check sizes are smaller. Start building momentum locally before approaching Sand Hill Road.
Consider Revenue-Based Financing: As you start generating revenue (Phase II-III), revenue-based financing firms like Lighter Capital or Clearco provide non-dilutive capital based on monthly revenue. This can supplement or reduce equity needs.
Document Everything: Every investor conversation, every piece of feedback, every concern raised—document it. This becomes incredibly valuable data for refining your pitch and understanding what resonates.
Red Flags to Avoid:
Investors Asking for Fees: Legitimate investors never charge fees to evaluate your opportunity. If someone asks for money to "review your deal" or "introduce you to their network," run away.
Pressure to Accept Terms Quickly: Good investors give you time to review terms, consult attorneys, and make informed decisions. Pressure tactics signal problems.
Investors Without Domain Expertise: An investor who doesn't understand healthcare, can't evaluate your technology, and has no relevant network adds little beyond capital. Be selective.
Terms That Give Away Control: As a first-time founder, you're vulnerable to unfavorable terms. Have experienced attorney review ALL term sheets before acceptance.
Your Most Valuable Asset:
Your most valuable asset in fundraising is not your pitch deck or financial projections—it's your authentic passion for the mission. Investors can teach you to refine unit economics or adjust your TAM calculation. They can't teach you to care about patients falling through cracks in the healthcare system.
Lead with mission. Back it up with mathematics. Close with execution plan.
You're not just raising capital. You're recruiting partners for a decade-long journey to transform healthcare.

This comprehensive framework provides everything you need to execute professional, effective investor outreach through appropriate channels. The specific contact information you need should come through relationship building, mutual introductions, and official application processes—not through directories of phone numbers.
Would you like me to develop any portion of this framework in more detail, such as creating your investor pitch deck content, drafting specific outreach email templates, or developing your grant application strategy?